422 related articles for article (PubMed ID: 23150626)
1. Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers.
Aifa A; Gueudry J; Portmann A; Delcampe A; Muraine M
Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8181-5. PubMed ID: 23150626
[TBL] [Abstract][Full Text] [Related]
2. Neurotrophic Keratopathy: Therapeutic Approach Using a Novel Matrix Regenerating Agent.
Guerra M; Marques S; Gil JQ; Campos J; Ramos P; Rosa AM; Quadrado MJ; Murta JN
J Ocul Pharmacol Ther; 2017 Nov; 33(9):662-669. PubMed ID: 28910175
[TBL] [Abstract][Full Text] [Related]
3. Matrix Regeneration Therapy: A Case Series of Corneal Neurotrophic Ulcers.
Arvola RP; Robciuc A; Holopainen JM
Cornea; 2016 Apr; 35(4):451-5. PubMed ID: 26845313
[TBL] [Abstract][Full Text] [Related]
4. Topical treatment with nerve growth factor for corneal neurotrophic ulcers.
Lambiase A; Rama P; Bonini S; Caprioglio G; Aloe L
N Engl J Med; 1998 Apr; 338(17):1174-80. PubMed ID: 9554857
[TBL] [Abstract][Full Text] [Related]
5. [Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report].
De Monchy I; Labbé A; Pogorzalek N; Gendron G; M'Garrech M; Kaswin G; Labetoulle M
J Fr Ophtalmol; 2012 Mar; 35(3):187.e1-6. PubMed ID: 22015067
[TBL] [Abstract][Full Text] [Related]
6. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis.
Yoon KC; You IC; Im SK; Jeong TS; Park YG; Choi J
Ophthalmology; 2007 Sep; 114(9):1637-42. PubMed ID: 17382396
[TBL] [Abstract][Full Text] [Related]
7. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration.
Tan MH; Bryars J; Moore J
Cornea; 2006 Apr; 25(3):352-5. PubMed ID: 16633039
[TBL] [Abstract][Full Text] [Related]
8. Topical treatment with nerve growth factor for neurotrophic keratitis.
Bonini S; Lambiase A; Rama P; Caprioglio G; Aloe L
Ophthalmology; 2000 Jul; 107(7):1347-51; discussion 1351-2. PubMed ID: 10889110
[TBL] [Abstract][Full Text] [Related]
9. Autologous serum application in the treatment of neurotrophic keratopathy.
Matsumoto Y; Dogru M; Goto E; Ohashi Y; Kojima T; Ishida R; Tsubota K
Ophthalmology; 2004 Jun; 111(6):1115-20. PubMed ID: 15177961
[TBL] [Abstract][Full Text] [Related]
10. [Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].
Chebbi CK; Kichenin K; Amar N; Nourry H; Warnet JM; Barritault D; Baudouin C
J Fr Ophtalmol; 2008 May; 31(5):465-71. PubMed ID: 18641578
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis.
Turkoglu E; Celik E; Alagoz G
Semin Ophthalmol; 2014 May; 29(3):119-26. PubMed ID: 23758337
[TBL] [Abstract][Full Text] [Related]
12. Healing of resistant corneal neurotrophic ulcers using a matrix regenerating agent.
Cochener B; Zagnoli C; Hugny-Larroque C; Derrien S
J Fr Ophtalmol; 2019 Feb; 42(2):159-165. PubMed ID: 30573293
[TBL] [Abstract][Full Text] [Related]
13. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
Pflugfelder SC; Massaro-Giordano M; Perez VL; Hamrah P; Deng SX; Espandar L; Foster CS; Affeldt J; Seedor JA; Afshari NA; Chao W; Allegretti M; Mantelli F; Dana R
Ophthalmology; 2020 Jan; 127(1):14-26. PubMed ID: 31585826
[TBL] [Abstract][Full Text] [Related]
14. Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy.
Yamada N; Matsuda R; Morishige N; Yanai R; Chikama TI; Nishida T; Ishimitsu T; Kamiya A
Br J Ophthalmol; 2008 Jul; 92(7):896-900. PubMed ID: 18511539
[TBL] [Abstract][Full Text] [Related]
15. Outcome of treatment of mooren ulcer with topical cyclosporine a 2%.
Tandon R; Chawla B; Verma K; Sharma N; Titiyal JS
Cornea; 2008 Sep; 27(8):859-61. PubMed ID: 18724142
[TBL] [Abstract][Full Text] [Related]
16. [Amniotic membrane graft in ocular surface disease. Prospective study with 31 cases].
Muraine M; Descargues G; Franck O; Villeroy F; Toubeau D; Menguy E; Martin J; Brasseur G
J Fr Ophtalmol; 2001 Oct; 24(8):798-812. PubMed ID: 11894530
[TBL] [Abstract][Full Text] [Related]
17. Effect of a New Matrix Therapy Agent in Persistent Epithelial Defects After Bacterial Keratitis Treated With Topical Fortified Antibiotics.
Chappelet MA; Bernheim D; Chiquet C; Aptel F
Cornea; 2017 Sep; 36(9):1061-1068. PubMed ID: 28691943
[TBL] [Abstract][Full Text] [Related]
18. RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies.
Brignole-Baudouin F; Warnet JM; Barritault D; Baudouin C
J Fr Ophtalmol; 2013 Nov; 36(9):740-7. PubMed ID: 23958066
[TBL] [Abstract][Full Text] [Related]
19. Autologous serum eyedrops in the treatment of aniridic keratopathy.
López-García JS; Rivas L; García-Lozano I; Murube J
Ophthalmology; 2008 Feb; 115(2):262-7. PubMed ID: 17675158
[TBL] [Abstract][Full Text] [Related]
20. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.
Koenig Y; Bock F; Kruse FE; Stock K; Cursiefen C
Cornea; 2012 Aug; 31(8):887-92. PubMed ID: 22362005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
